---
id: 200
title: Infections in the Elderly
category: special_populations
subcategory: geriatrics
tags: [elderly, geriatrics, atypical-presentation, UTI, pneumonia, nursing-home, frailty]
difficulty: medium
---

## Question

What are unique features of infections in elderly? Use **"Atypical Presentation (No Fever, Delirium), Polymicrobial, Higher Mortality, Avoid Fluoroquinolones"** framework.

## Answer

### **Atypical Presentations (Common):**

**Absence of Classic Signs:**
- **Afebrile or low-grade fever** (50% lack fever with serious infections)
- **Blunted inflammatory response** (↓WBC, ↓CRP)
- **No localizing symptoms** (e.g., pneumonia without cough, UTI without dysuria)

**Non-Specific Signs:**
- **Delirium/altered mental status** (most common presentation of infection)
- **Functional decline** (falls, decreased mobility, decreased PO intake)
- **Weakness, fatigue, "failure to thrive"**
- **Tachycardia, tachypnea** (without fever)

### **Common Infections:**

**Urinary Tract Infections (UTI):**

**Asymptomatic Bacteriuria (ASB):**
- **Prevalence:** 25-50% in nursing homes, 15-20% community-dwelling elderly
- **Do NOT treat** (except pre-urologic procedure, pregnancy)
- **Treatment increases resistance, *C. difficile* risk**

**Symptomatic UTI:**
- **Dysuria, urgency, frequency** (if present)
- **OR non-specific:** Delirium, falls, functional decline WITHOUT GU symptoms
- **Diagnosis:** Pyuria + positive culture + symptoms (NOT just positive urine culture)

**Treatment:**
- **Avoid fluoroquinolones** (Achilles tendon rupture, delirium, QT prolongation, *C. difficile*)
- **Preferred:** Nitrofurantoin (if eGFR >30), TMP-SMX, cephalosporins

**Pneumonia:**

**Presentation:**
- **Atypical:** Delirium, tachypnea, hypoxia WITHOUT cough/fever
- **Aspiration risk:** Dysphagia, stroke, dementia, Parkinson's

**Pathogens:**
- ***S. pneumoniae*, *H. influenzae*, *M. catarrhalis* (typical)
- **Aspiration:** Anaerobes, Gram-negatives (*Klebsiella*, *E. coli*)
- **Nursing home:** MDROs (MRSA, ESBL, *Pseudomonas*)

**Treatment:**
- **CAP:** Ceftriaxone + azithromycin OR levofloxacin (if low fluoroquinolone risk)
- **HCAP/aspiration:** Pip-tazo or carbapenem (cover MDRO, anaerobes)

**Skin and Soft Tissue Infections:**

**Cellulitis:**
- **Higher risk:** Venous insufficiency, lymphedema, diabetes, pressure ulcers
- **Pathogens:** *S. aureus*, streptococci, polymicrobial (if ulcers)

**Pressure Ulcers:**
- **Polymicrobial:** *S. aureus*, Gram-negatives, anaerobes
- **Osteomyelitis risk** (if deep ulcer, probe-to-bone positive)

***Clostridioides difficile* Infection:**
- **Higher incidence** (age >65 = risk factor)
- **More severe** (toxic megacolon, mortality)
- **Treatment:** Vancomycin 125mg PO QID × 10 days (fidaxomicin if available)

**Influenza / COVID-19:**
- **Higher mortality** in elderly
- **Vaccination essential** (annual flu, COVID-19 boosters)
- **Early antiviral treatment** (oseltamivir for flu within 48h, nirmatrelvir-ritonavir for COVID if eligible)

### **Polypharmacy Considerations:**

**Drug-Drug Interactions:**
- **Common:** Anticoagulants (warfarin + azithromycin/fluoroquinolones), antiarrhythmics, statins

**Renal Function:**
- **Adjust doses** for decreased eGFR (common in elderly)
- **Avoid nephrotoxic drugs** if possible (aminoglycosides, vancomycin monitoring)

**QT Prolongation:**
- **Azithromycin, fluoroquinolones** (use caution with other QT-prolonging drugs)

### **Avoid in Elderly (Beers Criteria):**

**Fluoroquinolones:**
- **Increased risk:** Achilles tendon rupture, peripheral neuropathy, aortic dissection, delirium, *C. difficile*
- **Use only if no alternatives**

**Nitrofurantoin (if eGFR <30):**
- **Ineffective** (inadequate urine concentrations)
- **Risk of pulmonary toxicity**

**Trimethoprim (high doses):**
- **Hyperkalemia risk** (especially with ACE-I, ARBs, spironolactone)

### **Nursing Home-Acquired Infections:**

**Risk Factors:**
- **Functional dependence** (ADL dependence, bedridden)
- **Devices:** Foley catheters, feeding tubes, tracheostomy
- **Antimicrobial exposure** (colonization with MDROs)

**Common Infections:**
- **UTI, pneumonia, skin/soft tissue** (pressure ulcers)
- ***C. difficile*, scabies outbreaks**

**Pathogens:**
- **MDROs:** MRSA, VRE, ESBL, CRE, *Pseudomonas*

**Empiric Treatment:**
- **Broader coverage** than community CAP/UTI (cover MDROs)

### **Immunosenescence:**

**Age-Related Immune Decline:**
- **Decreased T-cell function** (impaired cell-mediated immunity)
- **Blunted antibody response** (vaccines less effective)
- **Chronic inflammation** (elevated baseline cytokines)

**Implications:**
- **Higher infection risk**, **atypical presentations**, **delayed diagnosis**
- **Vaccine importance** (pneumococcal, influenza, COVID-19, shingles)

## Key Points

### **Delirium = Infection Until Proven Otherwise:**
- **Most common presentation** of serious infection in elderly
- **Evaluate for:** UTI, pneumonia, intra-abdominal infection, *C. difficile*

### **Do NOT Treat Asymptomatic Bacteriuria:**
- **Prevalence 25-50%** in nursing homes
- **Treatment increases resistance**, *C. difficile* risk
- **Only treat symptomatic UTI**

### **Avoid Fluoroquinolones:**
- **Beers Criteria:** Avoid unless no alternatives
- **Risks:** Tendon rupture, delirium, *C. difficile*, QT prolongation

### **Vaccination Critical:**
- **Pneumococcal:** PCV20 (≥65 years)
- **Influenza:** Annual
- **COVID-19:** Updated boosters
- **Shingles:** Shingrix (≥50 years)

### **Adjust for Renal Function:**
- **Decreased eGFR common** in elderly
- **Dose adjust:** Renally cleared antibiotics (β-lactams, vancomycin, fluoroquinolones)

### **Clinical Pearls:**
- **Atypical presentation:** Delirium, falls, functional decline (NO fever/localizing symptoms)
- **Do NOT treat asymptomatic bacteriuria** (common in nursing homes)
- **Avoid fluoroquinolones** (tendon rupture, delirium, *C. difficile*)
- **Vaccination:** Pneumococcal (PCV20), annual flu, COVID-19, shingles (Shingrix)
- **Nursing home:** MDROs common (MRSA, ESBL, *Pseudomonas*) → broader empiric coverage

## Sources

- [IDSA: Infections in Elderly Guidelines 2024]
- [AGS Beers Criteria 2024]

## Media

N/A
